Recent data presented by Boffa, et al. at the American Society of Clinical Oncology (ASCO 2016) meeting, which utilized the Epic PD-L1 assay to demonstrate higher burden of PD-L1+ CTCs is a poor prognostic factor in lung cancer compared those patients with the highest burden of PD-L1+ CTCs to low/negative PD-L1+ CTCs. The gene discussed is CD274; the disease is lung cancer.